Neurovascular innovation company Scientia Vascular announced it raised $14 million in growth funding led by Piper Sandler Merchant Banking. This funding will enable Scientia to continue commercializing the next generation of neurovascular tools, providing new possibilities for treating a variety of neurovascular disease states for patient benefit.
Scientia is transforming the way diseases of the cerebral vasculature are treated. Renowned for transforming the industry with microfabrication, Scientia currently offers the most comprehensive portfolio of neurovascular guidewires on the market and has applied the same innovative technologies, design principles, and precision machinery to develop highly differentiated microcatheters and aspiration catheters. As Scientia moves ahead, microfabrication will continue serving as the platform for innovating technologies that more effectively address a wide array of neurovascular disease states.
KEY QUOTES:
“Scientia exemplifies many of the attributes we look for in an investment partner: a strong team with a long track record of innovation and success, differentiated and groundbreaking technology that improves patient outcomes, a large and growing market opportunity and strong financial performance. We look forward to partnering with John Lippert and the rest of the team at Scientia to support the next stage of the company’s growth.”
– Tom Schnettler, managing director at Piper Sandler Merchant Banking
“Our mission at Scientia is to develop and apply state-of-the-art technology to care for patients with unmet needs. We are grateful for the support of Piper Sandler Merchant Banking as we look to accelerate our growth following the launch of our Plato 17 and Socrates 38 neurovascular catheters.”
– John Lippert, founder and CEO of Scientia
